MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, SNDX had -$19,268K decrease in cash & cash equivalents over the period. -$323,167K in free cash flow.

Cash Flow Overview

Change in Cash
-$19,268K
Free Cash flow
-$323,167K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from maturities of shor...
    • Stock-based compensation
    • Accrued expenses and other curre...
    • Others
Negative Cash Flow Breakdown
    • Net loss
    • Purchases of short and long-term...
    • Collaboration (payable) receivab...
    • Others

Cash Flow
2025-12-31
Net loss
-285,422
Depreciation
6
Accretion of investments
10,753
Non-cash operating lease expense
946
Stock-based compensation
47,503
Amortization of debt issuance costs
228
Provision for credit losses
3,667
Inventory reserves
163
Accounts receivable
30,394
Inventory
32,091
Prepaid expenses and other current assets
14,542
Collaboration (payable) receivable, net
-42,976
Other receivable
6,436
Other assets
0
Accounts payable
4,954
Accrued expenses and other current liabilities
42,167
Net cash used in operating activities
-322,980
Purchases of property and equipment
187
Purchases of short and long-term investments
195,807
Proceeds from maturities of short-term investments
486,030
Net cash provided by (used in) investing activities
290,036
Proceeds from issuance of common stock in follow-on public stock offering, net-Follow On Public Offerings
0
Proceeds from issuance of common stock in follow-on public stock offering, net-At The Market Stock Offering
0
Proceeds from purchase and sale agreement, net
0
Proceeds from espp
1,538
Proceeds from stock option exercises
12,138
Net cash provided by financing activities
13,676
Net (decrease) increase in cash, cash equivalents and restricted cash
-19,268
Cash, cash equivalents and restricted cashbeginning of year
154,300
Cash, cash equivalents and restricted cashend of year
135,032
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from maturitiesof short-term...$486,030K Proceeds from stockoption exercises$12,138K Proceeds from espp$1,538K Net cash provided by(used in) investing...$290,036K Net cash provided byfinancing activities$13,676K Canceled cashflow$195,994K Net (decrease)increase in cash, cash...-$19,268K Canceled cashflow$303,712K Stock-based compensation$47,503K Accrued expenses andother current...$42,167K Accounts payable$4,954K Provision for creditlosses$3,667K Non-cash operating leaseexpense$946K Amortization of debt issuancecosts$228K Inventory reserves$163K Depreciation$6K Purchases of short andlong-term investments$195,807K Purchases of property andequipment$187K Net cash used inoperating activities-$322,980K Canceled cashflow$99,634K Net loss-$285,422K Collaboration (payable)receivable, net-$42,976K Inventory$32,091K Accounts receivable$30,394K Prepaid expenses andother current assets$14,542K Accretion of investments$10,753K Other receivable$6,436K

Syndax Pharmaceuticals Inc (SNDX)

Syndax Pharmaceuticals Inc (SNDX)